The mechanisms of diabetic painful neuropathy are complicated and comprise of peripheral and central pathophysiological phenomena. A number of proinflammatory cytokines are involved in this process.
a b s t r a c t
The mechanisms of diabetic painful neuropathy are complicated and comprise of peripheral and central pathophysiological phenomena. A number of proinflammatory cytokines are involved in this process.
Tumor necrosis factor a (TNF-a) is considered to be one of the major contributors of neuropathic pain.
In order to explore the potential role of inflammation in the peripheral nervous system of Type 1 diabetic animals with painful neuropathy, we investigated whether TNF-a is a key inflammatory mediator to the diabetic neuropathic pain and whether continuous delivery of TNFa soluble receptor from damaged axons achieved by HSV vector mediated transduction of DRG would block or alter the pain perception in animals with diabetic neuropathy. Diabetic animals exhibited changes in threshold of mechanical and thermal pain perception compared to control rats and also demonstrated increases in TNFa in the DRG, spinal cord dorsal horn, sciatic nerve and in the foot skin, 6 weeks after the onset of diabetes. Therapeutic approaches by HSV mediated expression of p55 TNF soluble receptor significantly attenuated the diabetes-induced hyperalgesia and decreased the expression of TNFa with reduction in the phosphorylation of p38MAPK in the spinal cord dorsal horn and DRG. The overall outcome of this study suggests that neuroinflammatory activation in the peripheral nervous system may be involved in the pathogenesis of painful neuropathy in Type 1 diabetes which can be alleviated by local expression of HSV vector expressing p55 TNF soluble receptor.
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Introduction
Painful neuropathy is a common, difficult to treat complication of diabetes. The pathogenesis of diabetic neuropathy is complex and involves multiple pathways. Lack of success in preventing neuropathy even with successful treatment of hyperglycemia suggests the presence of early mediators between hyperglycemia-induced metabolic and enzymatic changes in functional and structural properties of the nervous system. Metabolic changes induced by hyperglycemia lead to dysregulation of cytokines which can cause pain-related symptoms (Skundric and Lisak, 2003) . Approximately 20-24% of diabetes patients experience neuropathic pain (Schmader, 2002) . Increasing evidence shows that inflammatory cytokines may participate in the pathogenesis of insulin resistance and its complications (Fernandez-Real and Ricart, 2003) . Subjects with Type 1 diabetic (T1D) neuropathy have shown an increase in plasma concentrations of inflammatory markers that are involved in insulin resistance (Goldberg, 2009; GonzalezClemente et al., 2007) . Increased level of tumor necrosis factor alpha (TNFa) is often demonstrated in patients with diabetic neuropathy, regardless of their glycemic control and cardiovascular risk factors that are associated with insulin resistance (Averill and Bornfeldt, 2009; King, 2008) . Patients with painful neuropathy have shown increased IL-2 and TNFa mRNA and protein levels in blood (King, 2008) . Studies have shown that patients with painful diabetic neuropathy (PDN) exhibit a different serum immune profile compared to patients with painless diabetic neuropathy which suggests that immune markers in blood are associated with diabetic neuropathic pain (Doupis et al., 2009; Uceyler et al., 2007) . Results from these studies suggest that TNFa may play a pathogenic role in the development of diabetic neuropathy (Gonzalez-Clemente et al., 2005 Abbreviations: PDN, painful diabetic neuropathy; T1D, Type 1 diabetes; DRG, dorsal root ganglia; IL-2, interleukin-2; TNF, tumor necrosis factor; TNFsR, soluble TNF receptors.
